12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Company News  |  Other News

Biota infectious news

HHS's Biomedical Advanced Research and Development Authority awarded Biota a contract worth up to $231 million over five years to develop and commercialize its laninamivir ( CS-8958) influenza vaccine in the U.S.


Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >